Knight Therapeutics commits to Forbion's third life sciences fund
European life sciences venture capital firm Forbion Capital Partners has closed its third fund, Forbion Capital Fund III (FCF III), at 183 million euros (US$208 million). Among the fund's limited partners was strategic investor Knight Therapeutics Inc (TSX: GUD), a Canadian specialty pharmaceutical company. Early last year, Forbion led the $13.5 million Series B financing of enGene Inc, a Montréal-based developer of novel DNA-based therapeutics.
12 April 2016•4 mins read
